Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JSKN016HC |
| Synonyms | |
| Therapy Description |
Limited information is currently available on JSKN016HC, a putative subcutaneously-delivered antibody-drug conjugate (ADC) targeting ERBB3 (HER3) and TROP2 (Mar 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JSKN016HC | JSKN-016HC|JSKN 016HC | HER3 (ERBB3) Antibody 29 TROP2 Antibody 19 | Limited information is currently available on JSKN016HC, a putative subcutaneously-delivered antibody-drug conjugate (ADC) targeting ERBB3 (HER3) and TROP2 (Mar 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07475559 | Phase I | JSKN016HC | JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors | Not yet recruiting | AUS | 0 |